Search results for: Market Access
Filter search results
Funding Challenges in the Malaysian Health Care System
7 January 2020
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
…disrupt the insurance market, making it difficult to support private insurance. Moreover, personalised medicine promotes the use of accompanying diagnostic tests and populations screening, both of which have implications for…
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
…without an effective market (a ‘pull’ incentive) there will not be enough new antibiotics. Solving the value assessment challenge. Value assessment of new drugs is typically based around RCTs to…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…is seven years since the NICE Decision Support Unit published analysis of how this counter-intuitive situation arises. Combination therapies continue to come to market, often at prices presenting challenges to…
Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic
21 April 2021
…and liability and more on volumes. This may, to some extent, explain why manufacturers have prioritised these two markets over the EU [a, b, c, h]. The vaccination rollout puzzle…
OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare
7 September 2021
…for prescription drugs used through Medicare which will also influence prices in the commercial market. WHY ARE WE COVERING H.R.3? H.R. 3 is important because of its potential impact. Recent…
No Smoking Day 2022: Reflecting on OHE Projections from 1994
9 March 2022
…Disease Study 2019 (GBD, 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020. Available from http://ghdx.healthdata.org/gbd-results-tool. Henriksen L (2012) Comprehensive tobacco marketing restrictions: promotion, packaging, price…
ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
6 June 2022
…that there is market failure in terms of collection of real-world evidence post-launch, as it is unclear who should bear this cost: the result is that data is undersupplied. This…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
The cohort of cancer drugs included are the ten approved by the EMA during 2003–2005. This time period was chosen based on the assumption that cancer drugs on the market…